Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
13 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc." is generating significant coverage in the Business category, with 13 articles from 13 distinct sources tracked by PULSE so far.
Outlets currently covering the story include BioPharma Dive, FirstWord Pharma, qz.com and Reuters. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 149d ago.
Quick answers
Why is "Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc." trending?
Because 13 independent news sources published 13 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (13)
- Biogen adds more immune drugs in $1B buyout of secretive startup RayThera BioPharma Dive · 152d ago
- Biogen snaps up RayThera in $1B immunology deal FirstWord Pharma · 152d ago
- Biogen acquires RayThera in deal worth up to $1 billion qz.com · 152d ago
- Biogen targets immunology growth with $1 billion RayThera deal Reuters · 152d ago
- Biogen Inc. entered into a definitive agreement to acquire RayThera, Inc. from Foresite Capital Management, LLC, OrbiMed Advisors LLC, TTM Capital and others for $1 billion. marketscreener.com · 152d ago
- Needham reiterates Buy on Biogen stock after RayThera acquisition Investing.com · 152d ago
- Needham reiterates Buy on Biogen stock after RayThera acquisition By Investing.com Investing.com Canada · 152d ago
- Biogen inks $1B RayThera buyout to bag preclinical immunology assets Fierce Biotech · 152d ago
- BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal Stocktwits · 152d ago
- Biogen Expects to Close Deal in 3Q Moomoo · 152d ago
- Biogen (BIIB) to Acquire RayThera Inc. for Up to $1 Billion GuruFocus · 152d ago
- Biogen makes up to $1B deal for secretive anti-inflammatory biotech Endpoints News · 152d ago
- Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. Biogen · 152d ago
Topics
Related trends
OpenAI AI Pipeline Generates 948 Linux Root Escalation Exploits in 30-Hour Run
OpenAI’s GPT‑6 Cyber AI churned out 948 Linux privilege‑escalation bugs in a 30‑hour run, sparking a wave of tech‑industry scrutiny.
Rare and common genetic variants shape single-cell immune gene expression
New studies show rare and common DNA variants jointly steer immune cell activity, tightening the link between genetics and disease.
US Business Activity Expands, Prices Surge by Most Since 2022
US business activity remains near five-year highs as pricing pressures surge to their most significant levels since August 2022.
A preinvasive regulatory T cell axis for lung cancer interception
Recent scientific studies and medical reports examine a preinvasive regulatory T cell axis and immune fog for lung cancer interception.
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
Sanofi and Regeneron have deepened their immunology alliance in a deal worth up to $8 billion to secure early-stage assets and a Dupixent successor.
Trump plugs $54 billion natural gas project in Alaska, flanked by a senator in a tight race
Dispute erupts as South Korea questions Trump's claim of funding for a massive Alaska natural gas pipeline project.